• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Autolus Therapeutics plc

    < Previous 1 2 Next >
    Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Announces Changes to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces publication in Blood Cancer Journal
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces publication in Nature Communications
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Announces Pricing of Underwritten Offering
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces publication in ACS Chemical Biology
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Announces Changes to its Board of Directors
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    Autolus Therapeutics announces participation in upcoming conferences
    From Autolus Therapeutics plc
    Via GlobeNewswire
    Tickers AUTL
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.